Remifemin(R) Homecoming for Enzymatic Therapy

GREEN BAY, Wis., May 25, 2005 /PRNewswire via COMTEX/ -- Enzymatic Therapy, a leader in the U.S. natural medicines industry, has acquired distribution rights for Remifemin(R), the #1 OB/GYN-recommended, non-prescription menopausal therapy. The company was first to handle the brand's distribution from 1995 to 2000. Then, Remifemin distribution went to GlaxoSmithKline Consumer Healthcare as the product entered mass markets. Now with Enzymatic Therapy's stellar growth and recent distribution acquisitions for Alluna(TM), SneezEze(TM) and Renouvelle(R), the timing is perfect for Remifemin to come back home to Enzymatic Therapy.

The transaction is effective June 20, 2005 when rights for the product will be transferred. Enzymatic Therapy will partner with Shaper & Brummer, GmbH & Co. KG, noted German manufacturer of Remifemin, to increase product distribution and market share.

As the leader in natural menopausal therapy, Remifemin is positioned to improve the well-being of millions of female baby boomers looking for a safe, natural alternative to HRT for menopausal symptoms. The product has a unique, standardized black cohosh extract that has been the subject of over 90 published scientific papers. A clinical study has shown a 70% reduction in hot flashes, night sweats, mood swings, irritability and the related occasional sleeplessness that can plague menopausal women.* A recent double- blind study confirms the significant reduction of menopausal symptoms, particularly in women in early stages of menopause, with no adverse side- effects (Obstet Gynecol105: 1074-83, 2005).* These clinical results, along with countless physician referrals and woman-to-woman recommendations, have made Remifemin the leading product for treatment of menopausal symptoms for nearly 50 years.

Part of the uniqueness of the product is the completely hormone-free formula made without plant-based estrogens that can affect breast and uterine cell growth. This makes Remifemin safe for use by women who cannot take estrogen because of a history of breast cancer.

Enzymatic Therapy sees even greater growth potential in Remifemin and the women's natural health category. The company will be implementing practitioner and consumer education programs to help more women discover Remifemin and its unique, safe and effective results.*

For further information, contact Enzymatic Therapy at 920-469-1313, ext. 1811 or email [email protected] .

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.